Free Trial

Cipher Pharmaceuticals (TSE:CPH) Stock Price Passes Below Fifty Day Moving Average - Should You Sell?

Cipher Pharmaceuticals logo with Medical background

Cipher Pharmaceuticals Inc. (TSE:CPH - Get Free Report) NASDAQ: CPHR shares crossed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of C$12.06 and traded as low as C$11.40. Cipher Pharmaceuticals shares last traded at C$11.47, with a volume of 24,879 shares trading hands.

Analysts Set New Price Targets

Separately, Canaccord Genuity Group set a C$12.50 price target on shares of Cipher Pharmaceuticals and gave the company a "hold" rating in a research note on Monday, April 7th.

Get Our Latest Analysis on CPH

Cipher Pharmaceuticals Stock Performance

The company has a current ratio of 2.00, a quick ratio of 2.67 and a debt-to-equity ratio of 41.22. The company has a market cap of C$222.62 million, a price-to-earnings ratio of 13.69 and a beta of 1.20. The stock has a 50 day moving average price of C$12.03 and a two-hundred day moving average price of C$13.73.

Insiders Place Their Bets

In related news, Director Harold Morton Wolkin sold 3,500 shares of the business's stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of C$13.49, for a total value of C$47,215.00. Company insiders own 42.00% of the company's stock.

About Cipher Pharmaceuticals

(Get Free Report)

Cipher Pharmaceuticals Inc is a specialty pharmaceutical company. Its products include Dermatology Products, Hospital Acute Care Products, and Out-Licensed Products among others. The company's geographical segments include Canada and the United States.

See Also

Should You Invest $1,000 in Cipher Pharmaceuticals Right Now?

Before you consider Cipher Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cipher Pharmaceuticals wasn't on the list.

While Cipher Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Make Your Money Work Harder: The Power of Dividend Investing
7 Cybersecurity Stocks Outperforming the Market Right Now
Markets in Rally Mode: Will Earnings Keep It Going?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines